Description

A study by StrategyHelix indicates that the global biological therapies for cancer market is expected to increase by US$ 50.0 billion from 2022 to 2028, garnering a CAGR of 8.2% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for biological therapies for cancer. The global biological therapies for cancer market is segmented on the basis of product, and region. Based on product, the global biological therapies for cancer market is categorized into CAR T-cell therapies, monoclonal antibodies, vaccines. The monoclonal antibodies segment held the largest share of the global biological therapies for cancer market in 2021 and is anticipated to hold its share during the forecast period. In terms of geography, the global biological therapies for cancer market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). Globally, North America made up the largest share of the biological therapies for cancer market.

The global biological therapies for cancer market is highly competitive. Some of the leading companies operating in the market are Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company (BMS), Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, Gilead Sciences Inc., GlaxoSmithKline plc (GSK), Janssen Pharmaceuticals Inc., Merck KGaA, Novartis International AG, Pfizer Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biological therapies for cancer market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: CAR T-cell therapies, monoclonal antibodies, vaccines
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global biological therapies for cancer market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Biological therapies for cancer market overview
Part 3. Market breakdown by product
– CAR T-cell therapies
– Monoclonal antibodies
– Vaccines
Part 4. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 5. Key companies
– Amgen Inc.
– AstraZeneca plc
– Bristol-Myers Squibb Company (BMS)
– Eli Lilly and Company
– F. Hoffmann-La Roche AG
– Genmab A/S
– Gilead Sciences, Inc.
– GlaxoSmithKline plc (GSK)
– Janssen Pharmaceuticals, Inc.
– Merck KGaA
– Novartis International AG
– Pfizer Inc.
About StrategyHelix
Disclaimer